L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease
| Autor: | E. W. Willoughby, G. L. Glasgow, J. W. Henley |
|---|---|
| Rok vydání: | 1974 |
| Předmět: |
Male
medicine.medical_specialty Parkinson's disease Nausea Vomiting Posture Decarboxylase inhibitor Blood Pressure Gastroenterology Malaise Levodopa Placebos Internal medicine Internal Medicine medicine Humans Hydrazine (antidepressant) Aged Clinical Trials as Topic Movement Disorders business.industry Carbidopa Parkinson Disease Middle Aged medicine.disease nervous system diseases Hydrazines Anesthesia Depression Chemical Drug Therapy Combination Female L-alpha-Methyldopa Drug Eruptions medicine.symptom business medicine.drug |
| Zdroj: | Australian and New Zealand journal of medicine. 4(4) |
| ISSN: | 0004-8291 |
| Popis: | Summary: Clinical experience with the use of L-alpha-methyldopa hydrazine (Carbidopa), an inhibitor of peripheral decarboxylation of L-dopa, in the treatment of idiopathic Parkinson's disease in twenty-six patients is described. Malaise, nausea and vomiting associated with L-dopa therapy were relieved in most patients. Improved motor function was marked in 25%, moderate in 50% of the patients, while the necessary dosage of L-dopa was reduced by a mean of 65%. It is concluded that the use of this decarboxylase inhibitor with L-dopa significantly improves the symptomatic treatment of Parkinson's disease, particularly in those patients in whom L-dopa dosage is limited by nausea and vomiting |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text